Literature DB >> 7731722

Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells.

M D Delgado1, A Lerga, M Cañelles, M T Gómez-Casares, J León.   

Abstract

The protein Max binds to c-Myc and the heterodimer c-Myc/Max seems to be the active form in vivo. While the expression of c-myc is extensively regulated, no major changes in max expression have been reported so far with respect to differentiation. We have studied the expression of c-Myc and Max during in vitro differentiation of the bipotent human myeloid leukemia K562 cell line. This cell model system allowed us to compare c-Myc and Max expression during differentiation along erythroid (induced by 1-beta-D-arabinofuranosyl-cytosine) and myelomonocytic lineages (induced by 12-0-tetradecanoylphorbol-13-acetate). We found that c-myc expression decreased as a result of both differentiating treatments. The expression level of max remained unchanged during myelomonocytic differentiation. In contrast, max mRNA and protein were dramatically down-regulated during erythroid differentiation of K562 cells, thus demonstrating that max gene is subjected to regulation during differentiation. We also studied the expression of the other two described members of the c-Myc network: mxi1 and mad. mxi1 expression increased during erythroid differentiation but was strongly down-regulated during myelomonocytic differentiation of K562. mad was constitutively expressed during K562 erythroid differentiation and slightly increased during induction of the myelomonocytic pathway. We have obtained K562 sublines stably transfected with a zinc-inducible c-myc gene. In these clones the overexpression of c-Myc did not interfere with TPA-induced myelomonocytic differentiation. In contrast, erythroid differentiation was significantly inhibited upon c-myc induction despite the down-regulation of endogenous max expression. These results suggest a differential role for c-Myc in the human myeloid cell differentiation depending on the cell lineage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731722

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Mad1 function is regulated through elements within the carboxy terminus.

Authors:  G Barrera-Hernandez; C M Cultraro; S Pianetti; S Segal
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.

Authors:  Juan C Acosta; Nuria Ferrándiz; Gabriel Bretones; Verónica Torrano; Rosa Blanco; Carlos Richard; Brenda O'Connell; John Sedivy; M Dolores Delgado; Javier León
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

3.  Sin3b interacts with Myc and decreases Myc levels.

Authors:  Pablo Garcia-Sanz; Andrea Quintanilla; M Carmen Lafita; Gema Moreno-Bueno; Lucia García-Gutierrez; Vedrana Tabor; Ignacio Varela; Yuzuru Shiio; Lars-Gunnar Larsson; Francisco Portillo; Javier Leon
Journal:  J Biol Chem       Date:  2014-06-20       Impact factor: 5.157

4.  Inhibition of cell proliferation by the Mad1 transcriptional repressor.

Authors:  M F Roussel; R A Ashmun; C J Sherr; R N Eisenman; D E Ayer
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

5.  A minimal regulatory region maintains constitutive expression of the max gene.

Authors:  M A Peters; K G Sollenberger; T L Kao; E J Taparowsky
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

6.  Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis.

Authors:  C Quéva; G A McArthur; B M Iritani; R N Eisenman
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

7.  Mad proteins contain a dominant transcription repression domain.

Authors:  D E Ayer; C D Laherty; Q A Lawrence; A P Armstrong; R N Eisenman
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 8.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 9.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

10.  Biological effects of a relatively low concentration of 1-beta-D-arabinofuranosylcytosine in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

Authors:  H Yamada; J Horiguchi-Yamada; M Nagai; S Takahara; T Sekikawa; T Kawano; K Itoh; S Fukumi; S Iwase
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.